Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 425 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust... May 29, 2026 Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 Six Months Immunogenicity of COVID-19 mRNA-based Vaccine in Patients with Actively... December 14, 2021 NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 Load more HOT NEWS Qué debo saber sobre los programas de emparejamiento de ensayos clínicos... Man Becomes Nervous About How Cop Acts During Ticket, Then He... Few People with Cancer Undergo Testing for Inherited Gene Mutations FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT...
